GIPR AND GLP-lR DUAL AGONIST POLYPEPTIDE AND USE THEREOF

Abstract

Provided are GIPR and GLP-1R co-agonistic polypeptides, or pharmaceutically acceptable salts, amides or esters thereof, and uses of the polypeptides, salts, amides or esters, including treatment of type II diabetes, obesity, overweight, and the like.

Description

(19) State Intellectual Property Office (12) Invention Patent Application (10) Application Publication Number (43) Application Publication Date (21) Application Number 202580003372.6 (22) Application Date 2025.05.09 (66) Domestic Priority Data 202410580912.4 2024.05.11 CN 202510512619.9 2025.04.23 CN (85) PCT International Application Entering National Phase Date 2025.12.24 (86) PCT International Application Application Data PCT / CN2025 / 093640 2025.05.09 (87) PCT International Application Publication Data WO2025 / 237168 ZH 2025.11.20 (71) Applicant Shijiazhuang Zhongqi Pharmaceutical Technology Co., Ltd. Address 050035 No. 896, Zhongshan East Road, High-tech Zone, Shijiazhuang City, Hebei Province (72) Inventors: Li Chunlei, Jiang Tian, ​​Zhang Xiaojun, Liang Xue, Chen Haikun, Zhang Xiaolin, Qiu Yanan, Li Min, Wang Chao, Yang Wenning, Wang Weiguo (74) Patent Agency: Beijing Yingsaijia Hua Intellectual Property Agency Co., Ltd. 11204 Patent Attorneys: Yi Shuo, Hong Xin (51) Int.Cl. C07K 14 / 00 (2006.01) C07K 14 / 575 (2006.01) A61K 38 / 16 (2006.01) A61P 3 / 04 (2006.01) A61P 3 / 10 (2006.01) (54) Invention Title: GIPR and GLP-1R Co-activating Peptide and Its Uses (57) Abstract: Provides information on GIPR and GLP-1R co-activating peptides, or pharmaceutically acceptable salts, amides, or esters thereof, and their uses, including the treatment of type II diabetes, obesity, or overweight. CN 121620523 A 2026.03.06 CN 1 21 62 05 23 A

Images